You are here

  • Home
  • Archive
  • Volume 32, Issue 1
  • Did Philip Morris International use the e-cigarette, or vaping, product use associated lung injury (EVALI) outbreak to market IQOS heated tobacco?

Article info

Article menu

This article has a correction. Please see:

Download PDFPDF
Industry watch
Did Philip Morris International use the e-cigarette, or vaping, product use associated lung injury (EVALI) outbreak to market IQOS heated tobacco?

Authors

  • John W Ayers Department of Medicine, University of California San Diego, La Jolla, California, USA Center for Data Driven Health at the Qualcomm Institute, University of California San Diego, La Jolla, California, USA PubMed articlesGoogle scholar articles
  • Eric C Leas Center for Data Driven Health at the Qualcomm Institute, University of California San Diego, La Jolla, California, USA Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, USA PubMed articlesGoogle scholar articles
  • Mark Dredze Department of Computer Science, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Theodore L Caputi Department of Economics, Massachusetts Institute of Technology, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Shu-Hong Zhu Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, USA PubMed articlesGoogle scholar articles
  • Joanna E Cohen Institute for Global Tobacco Control, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr John W Ayers, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA; ayers.john.w{at}gmail.com
View Full Text

Citation

Ayers JW, Leas EC, Dredze M, et al
Did Philip Morris International use the e-cigarette, or vaping, product use associated lung injury (EVALI) outbreak to market IQOS heated tobacco?
Tobacco Control 2023;32:131-132.

Publication history

  • Received March 5, 2020
  • Revised March 16, 2021
  • Accepted March 24, 2021
  • First published April 16, 2021.
Online issue publication 
December 14, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.